OmniAb, Inc. (NASDAQ:OABI) Shares Bought by State Street Corp

State Street Corp increased its stake in OmniAb, Inc. (NASDAQ:OABI) by 1.7% during the third quarter, HoldingsChannel.com reports. The fund owned 2,031,676 shares of the company’s stock after buying an additional 34,654 shares during the period. State Street Corp’s holdings in OmniAb were worth $8,594,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of OABI. Murchinson Ltd. acquired a new position in shares of OmniAb in the third quarter worth about $4,230,000. PDT Partners LLC purchased a new stake in shares of OmniAb in the 3rd quarter valued at approximately $123,000. Walleye Capital LLC acquired a new position in OmniAb in the 3rd quarter worth approximately $61,000. BBR Partners LLC grew its position in OmniAb by 250.0% during the 3rd quarter. BBR Partners LLC now owns 70,000 shares of the company’s stock worth $296,000 after purchasing an additional 50,000 shares in the last quarter. Finally, FMR LLC raised its stake in OmniAb by 10.6% during the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after purchasing an additional 13,324 shares during the period. 72.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on OABI. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Stock Up 0.6 %

Shares of NASDAQ:OABI opened at $3.59 on Friday. The firm has a fifty day moving average of $3.95 and a two-hundred day moving average of $4.13. OmniAb, Inc. has a 12-month low of $3.43 and a 12-month high of $6.72. The firm has a market capitalization of $506.97 million, a P/E ratio of -5.79 and a beta of -0.14.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.